Abstract
The ability of noncytolytic Lyt-1+,2- T cells immune to FBL-3 leukemia to effect eradication of disseminated FBL-3 was studied. Adult thymectomized, irradiated, and T-depleted bone marrow-reconstituted (ATXBM) B6 hosts were cured of disseminated FBL-3 by treatment with 180 mg/kg cyclophosphamide (CY) and adoptively transferred Lyt-1+,2- T cells obtained from congenic B6/Thy-1.1 donors immune to FBL-3. Analysis of the T cell compartment of ATXBM hosts treated and rendered tumor-free by this therapy revealed that the only T cells present in the mice were donor-derived Lyt-1+,2- T cells. In vitro stimulation of these T cells with FBL-3 tumor cells, which express class I but no class II major histocompatibility complex antigens, induced lymphokine secretion, but did not result in the generation of cytotoxic T lymphocytes (CTL). Thus, in a setting in which mice lack Lyt-2+ T cells, and in which no CTL of either host or donor origin could be detected, immune Lyt-1+,2- T cells, in conjunction with CY, mediated eradication of a disseminated leukemia. The results suggest that delayed-type hypersensitivity responses induced by immune T cells represent a potentially useful effector mechanism for in vivo elimination of disseminated tumor cells.
Full Text
The Full Text of this article is available as a PDF (830.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Badger C. C., Bernstein I. D. Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen. J Exp Med. 1983 Mar 1;157(3):828–842. doi: 10.1084/jem.157.3.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berendt M. J., North R. J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69–80. doi: 10.1084/jem.151.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Binz H., Fenner M., Engel R., Wigzell H. Studies on chemically induced rat tumors. II. Partial protection against syngeneic lethal tumors by cloned syngeneic cytotoxic T lymphocytes. Int J Cancer. 1983 Oct 15;32(4):491–500. doi: 10.1002/ijc.2910320417. [DOI] [PubMed] [Google Scholar]
- Cheever M. A., Greenberg P. D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol. 1980 Aug;125(2):711–714. [PubMed] [Google Scholar]
- Cheever M. A., Greenberg P. D., Fefer A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells. J Immunol. 1978 Dec;121(6):2220–2227. [PubMed] [Google Scholar]
- Cheever M. A., Greenberg P. D., Irle C., Thompson J. A., Urdal D. L., Mochizuki D. Y., Henney C. S., Gillis S. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol. 1984 May;132(5):2259–2265. [PubMed] [Google Scholar]
- Chesebro B., Wehrly K., Chesebro K., Portis J. Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol. 1976 Oct;117(4):1267–1274. [PubMed] [Google Scholar]
- Dailey M. O., Fathman C. G., Butcher E. C., Pillemer E., Weissman I. Abnormal migration of T lymphocyte clones. J Immunol. 1982 May;128(5):2134–2136. [PubMed] [Google Scholar]
- Dailey M. O., Pillemer E., Weissman I. L. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5384–5387. doi: 10.1073/pnas.79.17.5384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duprez V., Hamilton B., Burakoff S. J. Generation of cytolytic T lymphocytes in thymectomized, irradiated, and bone marrow-reconstituted mice. J Exp Med. 1982 Sep 1;156(3):844–859. doi: 10.1084/jem.156.3.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fernandez-Cruz E., Halliburton B., Feldman J. D. In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma. J Immunol. 1979 Oct;123(4):1772–1777. [PubMed] [Google Scholar]
- Fernandez-Cruz E., Woda B. A., Feldman J. D. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med. 1980 Oct 1;152(4):823–841. doi: 10.1084/jem.152.4.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
- Greenberg P. D., Cheever M. A., Fefer A. Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res. 1980 Dec;40(12):4428–4432. [PubMed] [Google Scholar]
- Greenberg P. D., Cheever M. A., Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med. 1981 Sep 1;154(3):952–963. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenberg P. D., Cheever M. A., Fefer A. H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol. 1981 Jun;126(6):2100–2103. [PubMed] [Google Scholar]
- Greenberg P. D., Cheever M. A. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol. 1984 Dec;133(6):3401–3407. [PubMed] [Google Scholar]
- Kelso A., Glasebrook A. L., Kanagawa O., Brunner K. T. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities. J Immunol. 1982 Aug;129(2):550–556. [PubMed] [Google Scholar]
- King D. P., Jones P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J Immunol. 1983 Jul;131(1):315–318. [PubMed] [Google Scholar]
- Kirch M. E., Hammerling U. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells. J Immunol. 1981 Aug;127(2):805–810. [PubMed] [Google Scholar]
- LeFrancois L., Bevan M. J. A reexamination of the role of LYT-2-positive T cells in murine skin graft rejection. J Exp Med. 1984 Jan 1;159(1):57–67. doi: 10.1084/jem.159.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leclerc J. C., Cantor H. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo. J Immunol. 1980 Feb;124(2):851–854. [PubMed] [Google Scholar]
- Lotze M. T., Line B. R., Mathisen D. J., Rosenberg S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980 Oct;125(4):1487–1493. [PubMed] [Google Scholar]
- Loveland B. E., Hogarth P. M., Ceredig R., McKenzie I. F. Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection. J Exp Med. 1981 May 1;153(5):1044–1057. doi: 10.1084/jem.153.5.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mills C. D., North R. J. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med. 1983 May 1;157(5):1448–1460. doi: 10.1084/jem.157.5.1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- North R. J., Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984 May 1;159(5):1295–1311. doi: 10.1084/jem.159.5.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982 Apr 1;155(4):1063–1074. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Plescia O. J., Smith A. H., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A. 1975 May;72(5):1848–1851. doi: 10.1073/pnas.72.5.1848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ramshaw I. A., McKenzie I. F., Bretscher P. A., Parish C. R. Discrimination of suppressor T cells of humoral and cell-mediated immunity by anti-Ly and anti-Ia sera. Cell Immunol. 1977 Jun 15;31(2):364–369. doi: 10.1016/0008-8749(77)90038-7. [DOI] [PubMed] [Google Scholar]
- Rosenstein M., Eberlein T. J., Rosenberg S. A. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. J Immunol. 1984 Apr;132(4):2117–2122. [PubMed] [Google Scholar]
- Rosenstein M., Rosenberg S. A. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies. J Natl Cancer Inst. 1984 May;72(5):1161–1165. [PubMed] [Google Scholar]
- Shimizu K., Shen F. W. Role of different T cells sets in the rejection of syngeneic chemically induced tumors. J Immunol. 1979 Mar;122(3):1162–1165. [PubMed] [Google Scholar]
- Stockman G. D., Heim L. R., South M. A., Trentin J. J. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol. 1973 Jan;110(1):277–282. [PubMed] [Google Scholar]
- Wilde D. B., Fitch F. W. Antigen-reactive cloned helper T cells. I. Unresponsiveness to antigenic restimulation develops after stimulation of cloned helper T cells. J Immunol. 1984 Apr;132(4):1632–1638. [PubMed] [Google Scholar]
- Wong G. H., Clark-Lewis I., McKimm-Breschkin L., Harris A. W., Schrader J. W. Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. J Immunol. 1983 Aug;131(2):788–793. [PubMed] [Google Scholar]